Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis

Abstract

Cardiac sarcoidosis (CS) remains an intriguing infiltrating disorder and one of the most important forms of inflammatory cardiomyopathy. Identification of patients with CS is of extreme importance because they are at higher risk of sudden death, and heart-failure progression. And while it remains a diagnostic conundrum, a great amount of experience has been accumulated over the last decade with the advent of fluorine-18 fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance with late gadolinium enhancement imaging. They have both proven to be advanced imaging techniques that provide important, and often complementary, diagnostic and prognostic information for the management of CS. However, they have also shown to have limitations, and, thus, there is a continued need for developing more specific imaging probes for identifying cardiac inflammation. The aim of the present manuscript is to provide the reader with a better understanding of the histopathology of the disease, how this potentially relates to noninvasive imaging detection, and the best strategies available for the diagnosis and management of patients with CS.

Sarcoidosis is a complex inflammatory condition of unknown etiology resulting from the growth of abnormal inflammatory cells in the form of nodules, referred to as noncaseating granulomas. These lesions are capable of affecting any organ in the body, including the heart. According to necropsy and imaging studies, cardiac involvement appears to affect approximately 20%−25% of patients with systemic sarcoidosis in the US,^1–3 although, the number may be higher in Japan.⁴ From a cardiovascular viewpoint, patients with cardiac sarcoidosis (CS) may remain asymptomatic or develop varying degrees of heart failure or rhythm disturbances ranging from complete heart block to sustained ventricular arrhythmias.⁵ In fact, sudden cardiac death is considered the leading cause of death (followed by progressive heart failure) among patients with CS.⁶ Consequently, multiple societies have recommended the use of implantable cardioverter defibrillators placement for primary prevention of sudden cardiac death in many of these patients.^7–10 Moreover, premier imaging societies including the American Society of Nuclear Cardiology, the Society of Nuclear Medicine and Molecular Imaging, the European Association of Nuclear Medicine, and the European Association of Cardiovascular Imaging have now published consensus documents and position statements that specify how to utilize imaging in evaluating patients with known or suspected CS.^11,12

However, despite significant advancements in cardiovascular imaging, the clinical diagnosis of CS remains challenging. Detection of noncaseating granulomas on endomyocardial biopsy (EMB) has a poor sensitivity (20%−30%) due to sampling error,^13,14 and it can be associated with significant peri-procedure complications.¹⁵ Consequently, the diagnosis of CS relies on noninvasive imaging. Fluorine-18 fluorodeoxyglucose (FDG) with positron emission tomography (PET) and cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) have become standard of care in the evaluation and management of patients with suspected CS, and are often used as a diagnostic alternative to EMB.^16,17 This review will provide an overview of histopathologic changes that occur in CS, and will discuss how different imaging techniques can be used to detect patients with known or suspected CS. In addition, we will discuss the complementary role of CMR and PET imaging and their clinical use in diagnosis and patient management.

HISTOPATHOLOGY FINDINGS IN CS

Knowledge of the most typical histopathologic changes in CS is useful for understanding the roles of different imaging techniques available in the evaluation of these patients. In addition, an understanding of the histopathology of sarcoidosis may explain why different tests may differ with respect to diagnosing various patterns of disease activity.

The histopathology hallmark of CS is the presence of noncaseating granulomas, mostly composed of macrophages and T lymphocytes (target for radionuclide molecular imaging). In later stages of disease, patients can develop varying degrees of myocardial fibrosis, best detected by CMR imaging.

Sarcoidosis can involve any part of the heart, including the coronary vessels, pericardium, and valves. However, the myocardium is the most frequently affected cardiac structure.^2,6,18 The left ventricle, and in particular the interventricular septum, is most commonly involved (Figure 1).^2,6 For reasons not wholly understood, granulomas are most often seen in the basal segments and commonly involve the mid-wall and subepicardium, whereas, the sub-endocardium and distal segments are infrequently involved.^6,18

Figure 1.

Distribution of regional myocardial involvement among patients with pathology-proven cardiac sarcoidosis. Caption based on one autopsy study¹⁸.

The cellular immune response of sarcoidosis in the heart is less well studied than in the lungs; however, similar to pulmonary sarcoidosis,^19,20 data from post-mortem studies indicate that CS can have at least three different histologic features (Table 1).^4,18 The first feature corresponds to a lymphocytic predominant infiltrate, with some interstitial edema, and few scattered epithelioid-cell granulomas or collection of histiocytes (not to confuse with giant cell myocarditis, which is associated with widespread myocyte necrosis). This is the least common type found in postmortem specimens. The identification of such activity would most likely require molecular imaging techniques, such as FDG PET. The second feature consists of predominantly well-formed granulomas, with varying degree of fibrosis, and appears to be the most frequently encountered type of CS. Both FDG PET and CMR may identify such features. The third feature is characterized by areas of replacement of the myocardium by fibrotic changes with few (if any) granulomas, and possibly some chronic interstitial lymphocytic cells. This pattern would be best detected by LGE-CMR or abnormal myocardial perfusion. Based on the available experience from systemic sarcoidosis, sarcoid tissue at any site may persist as active sarcoidosis, resolve, or progress to fibrosis.¹⁹ Unfortunately, longitudinal histological assessment of CS is lacking, which precludes ascertainment of the progression (or regression) from one feature to the other, along with their clinical implications. As such, we recommend that rather than using the term stages of disease—which implies a linear progression from one stage to the next—the term patterns of disease activity may instead be used.

Table 1.

Proposed histopathology features in cardiac sarcoidosis and their anticipated imaging findings

Characteristics	Predominantly lymphocytes	Predominantly granulomas	Predominantly scar
Histopathology finding	Lymphocytes, scattered macrophage giant cells	Well-formed granulomas and varying degrees of fibrosis	Predominant fibrosis with few (if any) granulomas
Myocardial perfusion	Normal	Normal or abnormal	Abnormal
Myocardial FDG uptake	Abnormal	Abnormal	Mostly normal
T2-weighted CMR	Possibly abnormal	Possibly abnormal	Normal
Myocardial LGE	Normal	Usually abnormal	Abnormal

CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement

ECHOCARDIOGRAPHY

In patients with CS, echocardiography is useful to assess left and right ventricular sizes, functions, and coexisting valvular disease. It may also be useful to assess the indirect effects of pulmonary sarcoidosis on right ventricular geometry function and afterload. Earlier manifestations of cardiac involvement may include new diastolic dysfunction or areas of asymmetric wall thickness (suggesting edema from active inflammation) with otherwise preserved left ventricular function.^21,22 More advanced phenotypes can range from global left ventricular dysfunction to scarred/thinned out segments, focal aneurysms or burnt out severe left/biventricular dysfunction.²³ The latter may be indistinguishable from any other form of advanced cardiomyopathy. Unfortunately, none of these findings described above are specific to CS.²⁴

When compared to CMR and FDG PET, echocardiography has low sensitivity for detection of CS, ranging from 25% to 65%.^25–27 In a recent publication, Kouranos et al demonstrated that CMR had a substantially higher sensitivity to detect cardiac involvement when compared to echocardiography, 97% vs 27%.²⁶ Given the above findings a negative echocardiogram should not be used to exclude cardiac involvement in patients with known extracardiac or suspected CS. Accordingly, in patients in whom further testing is needed to detect CS, FDG PET, or CMR should be considered as first-line testing options.

CARDIAC FDG PET

Cardiac FDG PET imaging is aimed at identifying metabolically active sarcoid lesions under the premise that granulomatous inflammatory cells are FDG-avid. The hallmark of CS on FDG PET imaging is the presence of focal or multifocal increased FDG uptake, especially when associated with perfusion defects (perfusion-metabolic mismatch; see examples in Figure 2). Patients that have no FDG uptake, but do have a resting myocardial perfusion defect, may still have cardiac involvement despite the absence of any active inflammation; a pattern often described as ‘‘burned out’’ sarcoidosis.

Figure 2.

Use of FDG PET/CT and myocardial perfusion imaging to identify various patterns of disease activity and estimate the likelihood of cardiac sarcoidosis. Adapted based on Vita et al⁴⁴.

When interpreting FDG PET images, there are certain patterns that signify a higher likelihood of having CS. For instance, patients that have multiple areas of focal FDG uptake, as well as rest perfusion defects, are more likely to have CS, especially if they also have extracardiac FDG uptake in a pattern which is consistent with sarcoidosis. On the other hand, isolated FDG uptake along the lateral wall which does not correspond to any perfusion defects, and appears homogenous, is associated with a lower likelihood CS. (Figure 2)

Since its first description in the late 1990s,²⁸ a substantial amount of data have accumulated on the clinical use of FDG PET in the evaluation and management of CS. However, owing to the lack of a gold standard, the true diagnostic performance of FDG PET (and other modalities) is not entirely known. Using the Japanese Ministry of Health and Welfare (JMHW) as the reference standard for diagnosis of CS, prior studies have reported a sensitivity of 89% and specificity of 78% for FDG PET, numbers that are actually comparable to the performance of LGE-CMR (sensitivity 75%−100% and specificity 76.9%−78%).^29–31 However, the JMHW criteria have limitations, including the lack of adequate validation, and the requirement for extra-CS in the diagnostic criteria. Consequently, isolated CS a well-described clinical entity that may occur in approximately 25% of cases³² cannot be diagnosed using these clinical criteria.³³ Thus, to this date, the true diagnostic accuracies of FDG PET and CMR remain incompletely elucidated.

FDG provides a unique role for assessing the response to anti-inflammatory therapy (Figures 3 and 4),³⁴ and risk stratification. Osborne and colleagues observed that in 23 patients with serial FDG PET scans, a reduction in intensity and extent of myocardial inflammation by FDG PET was associated with a significant improvement in left ventricular ejection fraction. Furthermore, Blankstein and colleagues evaluated 117 patients with known or suspected CS and showed that the presence of focal FDG uptake on cardiac PET identified patients at higher risk of death or ventricular tachycardia, even after adjusting for ejection fraction and other clinical factors.³⁵ Similarly, development of complete heart block in patients with sarcoidosis has been strongly associated with the presence of focal FDG uptake in the interventricular septum, and unlike subjects without myocardial inflammation on PET, heart block has the potential to recover in some patients with coexisting myocardial inflammation after steroid therapy.³⁶

Figure 3.

Clinical utility of FDG PET/CT for treatment response monitoring. Baseline whole body (A) and cardiac (B-C) FDG PET/CT images demonstrate extensive thoracic and cardiac inflammation in a patient with pulmonary sarcoidosis presenting with intermittent heart block. Following corticosteroid therapy, 5 months later, there is resolution of FDG resolution on whole body (D) and cardiac (E-F) FDG PET/CT.

Figure 4.

57-y/o male with pulmonary and ocular sarcoid presented with palpitations, which were attributed to NSVT. CMR showed small areas of focal mid myocardial LGE in the mid-inferior and mid-lateral wall (panel A, solid arrows). Subsequently, cardiac FDG PET identified active myocardial inflammation along the lateral wall (arrow in multiple panels). The latter responded to treatment with steroids, although a small amount of residual pulmonary FDG uptake persisted. (see panels B vs C for comparison of FDG uptake). The top two rows represent imaging prior to treatment; the bottom two rows represent imaging after treatment.

FDG has a number of limitations, the most important being that healthy myocardial cells can utilize glucose as their energy source, thereby compromising distinction between physiologic and pathologic FDG uptake. To circumvent this limitation, several strategies to suppress FDG uptake by normal myocardium have been described, including prolonged fasting, dietary switch to a lipid-rich/carbohydrate-deprived diet 24 hours before the exam, and use of intravenous heparin prior to FDG injection. Unfortunately, even after strict adhesion to these techniques, at least 10%−15% of FDG PET remain nondiagnostic due to incomplete FDG suppression,³⁷ thus making the distinction of pathologic from physiologic FDG uptake not possible in some cases. In addition, ischemic (hibernating) myocardium,³⁸ and the failing heart³⁹ can cause glucose upregulation from mechanisms other than inflammation, which may potentially yield further false positive scans. Furthermore, myocardial inflammation may be seen in other forms of dilated cardiomyopathy as well, and its presence has been recently associated with adverse myocardial remodeling and disease progression.⁴⁰ Finally, the radiation exposure from a typical cardiac FDG PET/CT protocol, including a limited whole body FDG PET (skull-base through mid-thighs), is not trivial, however; with the development of three-dimensional acquisition and advent of more sensitive PET systems, it is expected that radiation exposure will continue to decrease substantially in the years to come.⁴¹

CARDIAC MAGNETIC RESONANCE IMAGING

The use of CMR in CS is based on identifying myocardial LGE in a typical distribution. Gadolinium is a biologically inert contrast agent that after intravenous administration remains in areas of expanded extracellular space (e.g., most often fibrosis, but in some cases marked inflammation) thus allowing for its visualization on delayed images (usually 10 minutes after injection).⁴² While the presence of myocardial LGE is common in a number of nonischemic cardiomyopathies, there are certain patterns of myocardial involvement that are considered typical for sarcoidosis.^43,44

From a diagnostic perspective, the sensitivity (75%−100%) and specificity (76.9%−78%) of LGE-CMR have been reportedly comparable with FDG PET,^29–31 but these comparisons have used a suboptimal reference standard, as discussed above. However, CMR has a number of potential advantages over FDG PET that deserve consideration. First, the higher spatial resolution of CMR compared with PET allows for visualization of subcentimeter lesions as well as the distinction between subepicardium, mid-myocardium, and subendocardium involvement, features which are potentially helpful to distinguish among various alternative diagnoses. This is relevant as sarcoid heart disease can consist of both microscopic and macroscopic lesions.¹⁸ Yet, the vast majority of clinically relevant sarcoid-related lesions are macroscopic in the form of either granulomatous nodules and/or scar formation. In fact, the presence of LGE appears to be the strongest predictor for mortality and sustained ventricular arrhythmias among individuals with suspected CS, and has a very high negative predictive value for adverse outcomes in general and ventricular arrhythmic events in particular.^17,45 In a recent meta-analysis that included 694 patients with suspected sarcoidosis from 7 different studies, Hulten and colleagues observed that ventricular arrhythmias occurred only in patients with myocardial LGE, and the annualized incidence of all-cause mortality was significantly higher in patients with LGE (3.1%) than without LGE (0.6%; P = .04).⁴⁶

Another important advantage of CMR is the significantly low number of nondiagnostic scans, and the fact that no dietary preparation is required prior to testing. Obviously, CMR is not exempt from technical issues, including gating and respiratory motion artifacts,⁴⁷ which can affect the diagnostic quality of CMR, to the point of rendering it nondiagnostic in rare cases. Nevertheless, there is a higher nondiagnostic rate of PET due to incomplete FDG suppression, and thus CMR is often considered the most suitable initial test for evaluating patients with suspected CS.⁴⁸

On the other hand, CMR is usually contraindicated in patients with implantable cardiac devices, and administration of gadolinium is also contraindicated in patients with advanced renal dysfunction.⁴⁹ Another limitation is that unlike FDG, CMR cannot be reliably used to assess response to therapy.³⁴ However, in this respect, there are emerging data showing that the use of precontrast quantitative T2-weighted CMR imaging (T2-mapping), a well-established marker of tissue edema in acute myocardial infarction and myocarditis, may have the potential to serve as a marker of disease activity. A recent study showed that among patients with suspected CS, myocardial T2 signal was significantly higher in patients with electrocardiographic abnormalities and arrhythmias compared to those without dysrhythmias.⁵⁰ The same group also observed that compared to baseline (70.0 ± 5.5 ms), T2 signal decreased significantly after 4 months of immunosuppressant therapy (59.2 ± 6.1 ms; P = .017).⁵¹ While this preliminary data is intriguing, additional studies are needed to further define the role of T2-weighted imaging in detection of disease activity, especially since tissue edema has not been yet demonstrated to be a typical feature of sarcoidosis.

COMBINED USE OF CMR AND FDG PET

There is growing evidence supporting the combined use of CMR and FDG PET imaging for enhancing both the diagnostic and prognostic performance of evaluating patients with suspected CS (Figure 5).^44,52,53 Supporting the complementary value of this multimodality approach, Vita and colleagues recently categorized the likelihood of CS in 107 patients (Table 2) as follows: (1) no (< 10%); (2) possible (10%−50%); (3) probable (50%−90%); or (4) highly probable (> 90%). A final adjudicated diagnosis (including imaging, clinical data, and pathology) was ascertained by consensus and used as Reference.⁴⁴ In total, 85% had LGE on CMR, whereas 76% had abnormal FDG on PET. Among those with LGE, 66% had abnormal FDG uptake, supporting the notion that LGE cannot be reliably used to identify patients who may benefit from anti-inflammatory therapies. When added to CMR results, PET findings were used to reclassify 45% of patients as having a higher or lower likelihood of CS, 80% of them correctly reclassified based on the final adjudicated diagnosis.

Figure 5.

65 y/o male with known pulmonary and parotid sarcoidosis presented with unexplained syncope. CMR (panel A) revealing focal subepicardial LGE in the apical anterior and antero-septal wall (solid arrows), while FDG PET (panels B and C) demonstrated a large amount of left (white arrow) and right (arrowhead) ventricular myocardial inflammation.

Table 2.

Defining likelihood of cardiac sarcoidosis

Category	Probability of CS (%)	Potential clinical implications
No cardiac sarcoidosis	< 10	No further evaluation or treatment.
Possible cardiac sarcoidosis	< 50	Likelihood of CS low enough that treatment not recommended; further evaluation could be considered in the future in selected cases depending on clinical scenario.
Probable cardiac sarcoidosis	50–90	Likelihood of CS is sufficiently high to consider treatment. Further diagnostic testing could be considered, if it will impact patient management.
Highly probable sarcoidosis	> 90	Likelihood of CS is high. Treatment generally recommended, even if biopsy is not available or is negative. Further diagnostic testing not required.

Treatment refers to either immunosuppressive therapies (when inflammation is present) or to use of ICD for prevention of SCD, especially if other indications for such therapies is present

In another study, Dweck and colleagues also showed the importance of combining PET and CMR. The authors prospectively investigated 25 patients with clinical suspicion of CS on a hybrid PET-MR system.⁵² They observed that eight patients had neither characteristic sarcoid LGE nor increased FDG uptake, and the diagnosis of CS was then unlikely. In contrast, eight out of nine patients with characteristic sarcoid LGE pattern also had focally increased myocardial FDG uptake matching the location of LGE. This group was consistent with active CS, whereas, the subject without FDG uptake (who had known extra-CS) was felt to have inactive CS. The remaining eight patients demonstrated increased myocardial FDG uptake without LGE. Patients with matching LGE and focal FDG uptake tended to have relatively little variation in myocardial FDG activity between 10 and 70 minutes, whereas, patients with diffuse and focal on diffuse FDG uptake had a clear stepwise increment of myocardial FDG activity over time, starting at 10 minutes and extending possibly beyond 70 minutes, strongly suggesting that, in the absence of LGE, these latter patterns most likely represent physiologic (from incomplete suppression) rather than pathologic FDG uptake. Nevertheless, it is important to acknowledge the fact that focal and focal on diffuse FDG uptake without accompanying LGE may still represent early CS in a small proportion of patients with high pretest probability (e.g., heart block in a patient with known sarcoidosis).⁵⁴

In addition to its complementary diagnostic value, the classification of groups by PET and CMR appears to provide different risk profiles as well. This was suggested in another study where 56 patients with suspected CS were sequentially evaluated with PET/CT and MRI systems, and retrospectively followed for 2.6 years (IQR 1.2–4.1) for the occurrence of major events.⁵³ The main findings were that the risk of all-cause death and ventricular arrhythmic events (n = 16/56) was similarly elevated between LGE-positive/FDG-positive (n = 7/20, HR 10.1 [95% CI 1.2–84]) and LGE-positive/FDG-negative (n = 8/16, HR 13.3 [1.7–107]) individuals, in referenced to patients with absent LGE and FDG, whom had the best outcomes (n = 1/20). Of note, FDG-positive/LGE-negative patients were not documented in this study, which was most likely the result of excluding cases showing diffuse and focal on diffuse myocardial FDG uptake from the study. In addition, a number of LGE-positive/FDG-negative patients had neither typical LGE pattern nor clinical history of sarcoidosis; thus, it is possible that some of these cases may represent cardiomyopathies other than sarcoidosis. While limited in size, this study, together with the findings of Vita et al,⁴⁴ suggests that CMR may have a larger contribution than FDG PET when assessing prognosis.

Finally, with the advent of integrated PET-MR scanners, simultaneous acquisition of FDG PET and LGE-CMR is nowadays a reality. However, these systems remain very costly and limited to only a few centers in the world. Consequently, the vast majority of combined evaluations (at least in the near and intermediate future) will continue to be performed sequentially on stand-alone MRI and PET/CT scanners. A proposed diagnostic algorithm taking advantage of the information provided by CMR and FDG PET/CT is presented in Figure 6.

Figure 6.

Proposed algorithm for the evaluation of patients with suspected cardiac sarcoidosis.

FUTURE NUCLEAR TECHNIQUES FOR IMAGING INFLAMMATION

Despite its widespread use, FDG lacks specificity and is, thus, not an ideal tracer for the detection of myocardial inflammation. As a result, there is an ongoing effort to identify new potential molecular targets for the identification of CS, which unite at least the following two characteristics: (1) exhibiting minimal myocardial uptake under basal conditions so that differentiation of pathologic vs physiologic uptake can be facilitated, and (2) being a sensitive marker of inflammation. It is worth mentioning that the development of sarcoidosis-specific radiotracers seems a challenging task, especially since the condition itself remains a diagnosis of exclusion on histology, and since there is no adequate diagnostic reference standard for validating new tracers. Nevertheless, aside from their diagnostic capabilities, new tracers should also aid in assessing response to therapy.

When considering future targets for imaging inflammation, activated macrophages in sarcoidosis have been shown to overexpress the somatostatin receptor subtype 2 (sstr-2).^55,56 Indium-111 (In-111) penteotride (OctreoScan), and the PET agents, gallium-68 (Ga-68) DOTATOC, Ga-68 DOTATATE, and Ga-68 DOTA-NOC are radiopharmaceuticals that bind preferentially to sstr-2, and have an advantageous biodistribution for cardiac imaging as they lack cardiac uptake under baseline conditions.^57,58 Although originally developed for the detection of neuroendocrine tumors, somatostatin receptor-targeted (SSTR) scintigraphy has been shown to be of potential diagnostic value in patients with sarcoidosis localized to the lung, mediastinum, hilar lymph nodes,^59–62 and most recently, the heart (Figure 7).^63–66 In one small series among patients with myocarditis, including CS, Ga-68 DOTATOC was compared to LGE-CMR, and a close spatial relation between SSTR uptake and LGE was observed.⁶³ In a different study, Ga-68 DOTANOC was performed within 7 days from FDG PET in 19 patients with suspected CS. The JMHW criteria were used as the reference, and three patients were deemed as definitely having CS. The authors reported that FDG was rated as inconclusive in 11 out of 19 patients, whereas no DOTANOC scan was considered inconclusive. Similarly, FDG was positive in 1 out of 3 patients with CS, and negative/inconclusive in 14 out of 16 patients without sarcoidosis. In contrast, they found that Ga-68 DOTANOC was positive in 3 out of 3 patients with sarcoidosis and negative in 16 out of 16 patients without the condition. The authors concluded that SSTR PET imaging might carry a higher diagnostic accuracy than FDG PET. However, this study size is small, and the number of inconclusive scans (58%) was exceedingly high compared with current standards, and therefore, these data, although promising, should be taken with caution and interpreted as preliminary.

Figure 7.

Patient with cardiac sarcoidosis showing evidence of inflammation in the anterior septum (red arrow) by FDG PET/CT as well as by OctreoScan SPECT/CT.

Imaging cell proliferation is another appealing molecular target. F-18 3′-fluoro-3′-deoxythymidine (FLT) is a radiotracer that accumulates in high-turnover cells and has found important clinical applications in tumor proliferation imaging. After administration, FLT is taken up by cells and phosphorylated by thymidine kinase 1 (TK), leading to intracellular trapping. Thus, FLT is considered a marker of cellular TK activity, an enzyme closely related to cellular proliferation.⁶⁷ Myocardial FLT uptake is low in normal hearts.

Experimental data has shown that granulomatous inflammatory cells, including macrophages, epithelioid, and multinucleated cells, can exhibit both low-turnover and high-turnover behaviors within the same lymph node.⁶⁸ In preclinical studies, FLT uptake has been shown to be comparable to that of FDG in rat models of granulomatous disease,⁶⁹ and in recent studies FLT has been shown to accumulate in both extracardiac⁷⁰ and CS.^71,72 Additional studies are required to further evaluate the clinical utility of these novel probes for myocardial inflammation detection.

CONCLUSIONS/FUTURE DIRECTIONS

Despite significant recent developments, the diagnosis of CS remains challenging. Nevertheless, FDG PET and LGE-CMR have both proven to be advanced imaging techniques that provide important, and often complementary, diagnostic and prognostic information for the management of CS. As a result, current algorithms for diagnosing and treating individuals with suspected sarcoidosis should incorporate both CMR and FDG PET and identify subgroups in whom both tests may be needed (e.g., those in whom any one test is inconclusive, or the diagnosis is uncertain). Such an approach could aid in estimating the likelihood of CS and identify those who are most likely to benefit from immunosuppressive therapies. At the same time, more studies are needed relating how imaging findings could be used to enhance the type, duration, and intensity of immunosuppressive therapies. In addition, there is a need for developing more specific imaging probes, as well as serum biomarkers, for identifying cardiac inflammation.

Abbreviations

CS

Cardiac sarcoidosis

CMR

Cardiac magnetic resonance imaging

FDG

Fluorine-18 fluorodeoxyglucose

PET

Positron emission tomography

LGE

Late gadolinium enhancement